Apigenin suppresses bladder cancer progression by enhancing SIRT6-mediated NCOA2 deacetylation.
Background
Bladder cancer remains a significant health challenge, with current therapies often limited by recurrence and progression. Protein acetylation, a crucial post-translational modification, plays an increasingly recognized role in regulating tumor development. However, the identification of natural compounds that can effectively modulate these acetylation pathways to inhibit cancer progression is still an area of active research. Understanding these specific molecular vulnerabilities, particularly in metabolic reprogramming, could lead to novel therapeutic strategies.
Study Design
Researchers investigated the anti-cancer effects of Apigenin using both in vitro functional assays and dynamic xenograft models of bladder cancer. To elucidate the underlying mechanism, an integrated multi-omics approach was employed, combining various high-throughput techniques to analyze changes in gene expression, protein modification, and metabolic profiles. The study focused on identifying specific protein acetylation events and their downstream consequences on cellular energy metabolism and transcriptional activity, comparing Apigenin-treated cells/tumors against untreated controls.
Results
Apigenin effectively suppressed bladder cancer progression in both in vitro and xenograft models. Mechanistically, the study revealed that Apigenin enhances SIRT6-mediated deacetylation of Nuclear Receptor Coactivator 2 (NCOA2). This specific modification occurred at lysine 780 and 785 of NCOA2.
This site-specific deacetylation of
NCOA2bySIRT6potentiatedPPARαtranscriptional activity, leading to a significant reprogramming of cellular energy metabolism and disruption of mitochondrial membrane potential.
Clinically, reduced SIRT6 expression, coupled with elevated NCOA2 and mitochondrial/β-oxidation markers, correlated with metastatic progression in human bladder cancer patients. These findings collectively identify a novel SIRT6-NCOA2-PPARα signaling axis as a metabolic vulnerability in bladder cancer.
Key Findings
- Apigenin suppresses bladder cancer progression in preclinical models.
- Apigenin enhances
SIRT6-mediated deacetylation ofNCOA2. NCOA2deacetylation occurs specifically atlysine 780and785.- This modification potentiates
PPARαtranscriptional activity. - Apigenin reprograms cellular energy metabolism and disrupts mitochondrial membrane potential.
Why It Matters
This research identifies Apigenin as a promising natural compound for bladder cancer therapy, highlighting a novel mechanism involving the SIRT6-NCOA2-PPARα axis. For individuals interested in complementary approaches or novel drug targets, this suggests Apigenin's potential to disrupt cancer cell metabolism. The findings provide a strong rationale for further investigation into Apigenin or its derivatives as metabolic modulators in oncology. While preclinical, this work lays the groundwork for developing targeted interventions that exploit this newly identified metabolic vulnerability, potentially leading to future clinical trials and refined protocols for dietary or pharmacological interventions.
apigenin
bladder-cancer
sirt6
ncoa2
ppar-alpha
protein-acetylation